London-listed Open Orphan (AIM:ORPH ) has confirmed that its Covid-19 antibody microarray machine is now on-site at hVivo's laboratory in East London and is undergoing testing.
The move follows the company’s announcement last week that it has secured a contract with commercial-stage diagnostics firm Quotient to support COVID-19 antibody testing in the UK.
The European-focused rare and orphan drug services company told investors this morning that it expects to be fully operational within two weeks.
Upon becoming fully operational, Open Orphan said it will have the capability to undertake up to 3,000 tests a day, in line with expected performance as stated by Quotient.
Shares in Open Orphan were trading 18.15% higher at 15.3p on Monday morning.
The group also said this morning that it intends to enter into discussions with channel partners to secure testing volumes in order to secure new business.
Currently, market prices for home testing kits are ranging from around £70 to around £150.
Open Orphan added that it intends to supply testing capability to any channel partners it secures, who will then in turn deal with the end users and the final price points.
Follow News & Updates from Open Orphan here: